探索不同剂量地西他滨对骨髓增生异常综合征的临床效果

探索不同剂量地西他滨对骨髓增生异常综合征的临床效果
王浩;谢佳;刘秋艳;刘锋;宋艳萍
【期刊名称】《中国医学前沿杂志（电子版）》
【年(卷),期】2015(0)7
【摘要】ObjectiveTo analyze the safety and clinical effect of different doses of decitabine in the treatment of myelodysplastic syndrome (MDS).Method78 patients with MDS in our hospital from April 2012 to June 2014 were selected as objects of study, they were divided into A, B, C three groups by a random number table, and all were treated with decitabine, patients in group A adopted dose 15 mg/(m2•d), intravenous infusion> 1 hou r, 5 days a week; group B was 20 mg /(m2•d), intravenous infusion> 1 hour, 5 days a week; group C was 25 mg /(m2•d), intravenous infusion> 1 hour, 5 days a week; the three groups of patients were treated for 3 months consecutivly. Vascular endothelial growth factor (VEGF) levels, efficacy and adverse reactions before and after the treatment were compared.ResultVEGF level after treatment of patients in group B was lower than group A and group C (P<0.05). In group A, 8 cases were markedly effective, 7 cases effective, the total effective rate was 57.69%; in group B, 10 cases were markedly effective, 13 cases effective, the total effective rate was 88.46%, in group C, 9 cases were markedly effective, 12 cases effective, the total effective rate was 80.77%, the differences between the three groups were signiifcant (P<0.05), the differences between group
A and B, group C were signiifcant (P<0.05), the differences between group
B and group
C were not significant (P>0.05); the differences of the incidence of adverse reactions during the treatment between the three groups of patients were not signiifcant (P>0.05).ConclusionDecitabine can effectively treat MDS, a dose of 20 mg / (m2•d) has the best safety and clinical effect.%目的：分析不同剂量地西他滨对骨髓增生异常综合征（myelodysplastic syndrome，MDS）患者的安全性及临床治疗效果。

方法选取本院2012年4月至2014年6月78例明确诊断为MDS患者为研究对象，采用随机数表法分为A、B、C三组，均给予地西他滨治疗，A组患者给药剂量为15 mg/（m2•d），静脉滴注＞1小时，每周5天；B组为20 mg/（m2•d），静脉滴注＞1小时，每周5天；C组为25 mg/（m2•d），静脉滴注＞1小时，每周5天；三组患者均连续治疗3个月。

比较治疗前后三组患者血管内皮细胞生长因子（VEGF）水平、临床疗效及不良反应发生情况。

结果治疗后B组患者VEGF水平低于A、C组（P＜0.05）。

A组显效8例，有效7例，总有效率为57.69%；B 组显效10例，有效13例，总有效率为88.46%，C组显效9例，有效12例，总有效率为80.77%，三组比较差异显著（P＜005）， A组与B、C组比较差异显著（P＜0.05），B、C组比较无显著差异（P＞0.05）。

三组患者治疗期间不良反应发生率比较无显著差异（P＞0.05）。

结论地西他滨能够有效治疗MDS，剂量为20 mg/（m2•d）其安全性和临床效果最佳。

【总页数】4页(P88-91)
【作者】王浩;谢佳;刘秋艳;刘锋;宋艳萍
【作者单位】西安市中心医院西安市血液病研究所，西安710003;西安市中心医院西安市血液病研究所，西安710003;西安市中心医院西安市血液病研究所，西
安710003;西安市中心医院西安市血液病研究所，西安710003;西安市中心医院西安市血液病研究所，西安710003
【正文语种】中文
【相关文献】
1.小剂量地西他滨及阿糖胞甘治疗中高危骨髓增生异常综合征临床效果 [J], 苏杰
2.地西他滨联合半量CAG方案治疗骨髓增生异常综合征的临床效果探讨 [J], 顾惠慈
3.地西他滨治疗骨髓增生异常综合征和急性髓系白血病的临床效果 [J], 季晶
4.不同剂量地西他滨对骨髓增生异常综合征小鼠Beclin1蛋白表达的影响 [J], 董曼;王月莉
5.地西他滨联合HAG方案治疗骨髓增生异常综合征的临床效果观察 [J], 卢卫兰;刘晓娟;葛守辈
因版权原因，仅展示原文概要，查看原文内容请购买。